Evidence map›Paper›PMID 41820674›Full record

ArticleNature medicine2026

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.

Aurélie Ploquin, Rosemarie D Mason, LaSonji A Holman, Myra Happe, Alicia T Widge, Laura Novik, Ana M Ortega-Villa, Galina V Yamshchikov, Ingelise J Gordon, Abidemi Ola and 30 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05398796 (VRC 322/DMID 21-0016), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05398796 phase1completednot on this map

VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2022 to 2024Enrolled40ConditionsNipah Virus InfectionArmsmRNA -1215
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Aurélie Ploquin *Vaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-9796-9277
Rosemarie D Mason *Vaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
LaSonji A HolmanVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Myra HappeVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Alicia T WidgeVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Laura NovikVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ana M Ortega-VillaBiostatistics Research Branch, Division of Clinical Research, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Galina V YamshchikovVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ingelise J GordonVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Abidemi OlaVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Anita ArthurVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Pamela J M CostnerVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Floreliz MendozaVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jamie SaundersVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Xioalin WangVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
William R WhalenVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Joanna UtohVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jennifer CunninghamVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lorin N LoftusVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0197-4037
Ashley HeimannVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0009-0001-2960-9093
Katia KorzeniwskyVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Shayne F AndrewVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-7226-7757
Evan LambVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Shruthi Shyam SunderVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Amelia ThompsonVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Mary McDonaldVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kathryn E FouldsVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4418-6495
Nancy J SullivanVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jessica BahorichVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Emily E CoatesVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Rebecca J LoomisVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Barney S GrahamVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Karin BokVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Sunny HimansuModerna, Inc, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7954-9674
Brett LeavModerna, Inc, Cambridge, MA, USA.
Walla DempseyDivision of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
John H BeigelDivision of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4879-4941
Mario RoedererVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lesia K DropulicVaccine Research Center, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. dropulicl@niaid.nih.gov.ORCID http://orcid.org/0000-0003-1125-5597
VRC 322 study team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nipah virus (NiV) is a highly pathogenic, zoonotic paramyxovirus with pandemic potential. No licensed vaccines or treatments are available. Therefore, we conducted a phase 1, first-in-human, open-label, dose-escalation trial of a lipid nanoparticle mRNA vaccine, mRNA-1215, encoding a chimeric pre-fusion F (Pre-F) protein linked to glycoprotein G of a NiV Malaysian strain. Forty healthy adults, who met eligibility criteria, were enrolled into the 10-, 25-, 50- or 100-μg dose groups with ten participants per group. Each participant received two doses of mRNA-1215, intramuscularly, at a 4-week interval except for one participant in the 10-μg dose group who received only the first dose. All participants remained in the study until their final study visit. The primary outcome of vaccine safety and tolerability was determined by prespecified end points: the frequency and severity of solicited local and systemic adverse events (AEs), unsolicited AEs, safety laboratory measures, medically attended AEs, AEs of special interest, new chronic medical conditions and serious AEs. The most frequently reported local and systemic AEs were mild pain and tenderness at the injection site (n  = 33; 82%) and mild malaise (n  = 16; 40%), respectively. Overall, the vaccine was well tolerated. No serious AEs occurred during the study. mRNA-1215 elicited robust Pre-F and G binding antibody titers, the prespecified secondary end points. An exploratory analysis found that mRNA-1215 elicited neutralizing titers by 2 weeks after the prime in all dose groups. Responses increased after the boost and remained elevated for at least 1 year after vaccination. These findings demonstrate an initial overall favorable safety profile and immunogenicity results for a first-in-human, structure-based, chimeric mRNA Nipah virus vaccine. mRNA-1215 is a promising vaccine candidate for continued clinical development for populations at risk for regional and potentially larger outbreaks caused by Nipah virus. ClinicalTrials.gov identifier: NCT05398796 .

Indexed as

Henipavirus InfectionsNipah VirusRNA, MessengerViral VaccinesAdolescentAdultAntibodies, NeutralizingAntibodies, ViralFemaleHumansLiposomesMaleMiddle AgedmRNA VaccinesNanoparticlesViral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralLipid NanoparticlesLiposomesmRNA VaccinesRNA, MessengerViral Envelope ProteinsViral Fusion ProteinsViral Vaccines

Identifiers

PMID41820674
PMCPMC13099371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.